胰高血糖素样肽-1：人体食物摄入量的有效调节因子。
Glucagon-like peptide-1: a potent regulator of food intake in humans.
作者信息
Gutzwiller J P, Göke B, Drewe J, Hildebrand P, Ketterer S, Handschin D, Winterhalder R, Conen D, Beglinger C
机构信息
Kantonsspital Aarau, CH-5000 Aarau, Switzerland.
出版信息
Gut. 1999 Jan;44(1):81-6. doi: 10.1136/gut.44.1.81.
BACKGROUND/AIMS: Studies in animals suggest a physiological role for glucagon-like peptide-1-(7-36)-amide (GLP-1) in regulating satiety. The role of GLP-1 in regulating food intake in man has, however, not been investigated. Subjects-Sixteen healthy male subjects were examined in a double blind placebo controlled fashion.
METHODS
The effect of graded intravenous doses (0, 0.375, 0.75, and 1.5 pmol/kg/min) of synthetic human GLP-1 on food intake and feelings of hunger and satiety was tested in healthy volunteers.
RESULTS
Graded GLP-1 infusions resulted in a dose dependent reduction in food intake (maximal inhibition 35%, p<0.001 v control) and a similar reduction in calorie intake (32%; p<0.001). Fluid ingestion was also reduced by GLP-1 (18% reduction, p<0.01). No overt side effects were produced by GLP-1, but subjects experienced less hunger and early fullness in the period before a meal during GLP-1 infusion at the highest dose (p<0.05).
CONCLUSIONS
Intravenous infusions of GLP-1 decrease spontaneous food intake even at physiological plasma concentrations, implying an important role for GLP-1 in the regulation of the early satiety response in humans.
背景/目的：动物研究表明胰高血糖素样肽-1-（7-36）酰胺（GLP-1）在调节饱腹感方面具有生理作用。然而，GLP-1在调节人类食物摄入量中的作用尚未得到研究。受试者——16名健康男性受试者以双盲安慰剂对照方式接受检查。
方法
在健康志愿者中测试了合成人GLP-1的分级静脉剂量（0、0.375、0.75和1.5 pmol/kg/分钟）对食物摄入量以及饥饿和饱腹感的影响。
结果
分级输注GLP-1导致食物摄入量呈剂量依赖性减少（最大抑制率35%，与对照组相比p<0.001），卡路里摄入量也有类似程度的减少（32%；p<0.001）。GLP-1还使液体摄入量减少（减少18%，p<0.01）。GLP-1未产生明显副作用，但在最高剂量的GLP-1输注期间，受试者在餐前阶段感到饥饿减轻且较早产生饱腹感（p<0.05）。
结论
静脉输注GLP-1即使在生理血浆浓度下也会减少自发食物摄入量，这意味着GLP-1在调节人类早期饱腹感反应中起重要作用。
Zotero 插件